Your browser doesn't support javascript.
loading
Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.
Gu, Shuyan; Mu, Yiming; Zhai, Suodi; Zeng, Yuhang; Zhen, Xuemei; Dong, Hengjin.
Affiliation
  • Gu S; Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China.
  • Mu Y; Department of Endocrinology and Metabolism, Chinese PLA General Hospital, Chinese PLA Medical College, Beijing, China.
  • Zhai S; Department of Pharmacy, Peking University Third Hospital, Beijing, China.
  • Zeng Y; Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China.
  • Zhen X; Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China.
  • Dong H; Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou City, Zhejiang, China.
PLoS One ; 11(11): e0165629, 2016.
Article in En | MEDLINE | ID: mdl-27806087
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Benzhydryl Compounds / Acarbose / Diabetes Mellitus, Type 2 / Glucosides / Hypoglycemic Agents Type of study: Health_economic_evaluation / Prognostic_studies Country/Region as subject: Asia Language: En Journal: PLoS One Year: 2016 Type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Benzhydryl Compounds / Acarbose / Diabetes Mellitus, Type 2 / Glucosides / Hypoglycemic Agents Type of study: Health_economic_evaluation / Prognostic_studies Country/Region as subject: Asia Language: En Journal: PLoS One Year: 2016 Type: Article Affiliation country: China